Wave Life Sciences Ltd. (WVE) Discusses Positive Interim Phase I Data from INLIGHT Trial of WVE-007 for Obesity March 26, 2026 8:30 AM EDT
Company Participants
Kate Rausch – Head of Investor Relations
Paul Bolno – President, CEO & Director
Erik Ingelsson – Chief Scientific Officer
Christopher Wright – Chief Medical Officer
Conference Call Participants
Steven Seedhouse – Cantor Fitzgerald & Co., Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Cheng Li – Oppenheimer & Co. Inc., Research Division
Matthew Guggenbiller – BofA Securities, Research Division
Madison Wynne El-Saadi – B. Riley Securities, Inc., Research Division
Jiale Song – Jefferies LLC, Research Division
Jiayi Yuan – RBC Capital Markets, Research Division
Salim Syed – Mizuho Securities USA LLC, Research Division
William Maughan – Clear Street LLC., Research Division
Michael King – Rodman & Renshaw Research
Whitney Ijem – Canaccord Genuity Corp., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Catherine Novack – JonesTrading Institutional Services, LLC, Research Division
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Hello, and welcome to Wave Life Sciences Positive Interim Phase I Clinical Data from INLIGHT Trial of WVE-007 for Obesity Call. [Operator Instructions] Also, as a reminder, this conference is being recorded today.
I will now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs.
Kate Rausch
Head of Investor Relations
Thank you, operator. This morning, we issued a press release announcing Positive Interim Clinical Data from our ongoing Phase I INLIGHT Trial of WVE-007 in otherwise healthy individuals living with overweight or obesity. Our press release can be found in the Investor Relations section of our website, www.wavelifesciences.com. The slide presentation to accompany this call will be available on the website following the prepared remarks.
Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are
